公开(公告)号：US20180230114A1

公开(公告)日：2018-08-16

申请号：US15750067

申请日：2016-08-04

申请人： Chong Kun Dang Pharmaceutical Corp.

发明人： Jaekwang Lee ,  Yuntae Kim ,  Chang Sik Lee ,  Hyeseung Song ,  Dal-Yong Gwak ,  Jaeyoung Lee ,  Jung Taek Oh ,  Chang Gon Lee ,  Il Hyang Kim

IPC分类号： C07D271/10

摘要： The present invention relates to novel compounds having histone deacetylase 6 (HDAC6) in-hibitory activity, stereoisomers thereof or pharmaceutically acceptable salts thereof the use thereof for the preparation of therapeutic medicaments, pharmaceutical compositions containing the same, a method for treating diseases using the composition, and methods for preparing the novel compounds. The novel compounds stereoisomers thereof or pharmaceutically acceptable salts thereof according to the present invention have histone deacetylase (HDAC) inhibitory activity and are effective for the prevention or treatment of HDAC6-mediated diseases, including infectious diseases; neoplasms; endocrine, nutritional and metabolic diseases; mental and be-havioral disorders; neurological diseases; diseases of the eye and adnexa; cardiovascular diseases; respiratory diseases; digestive diseases; diseases of the skin and subcutaneous tissue; diseases of the musculoskeletal system and connective tissue; or congenital malformations, deformations and chromosomal abnormalities.

公开(公告)号：US20230147859A1

公开(公告)日：2023-05-11

申请号：US17904806

申请日：2021-02-25

申请人： CHONG KUN DANG PHARMACEUTICAL CORP.

发明人： Chang Kon Lee ,  Moo Sung Ko ,  Dal-Yong Gwak ,  Seok Hyoun Yun ,  Seo Young Lee ,  Hyunjin Michael Kim

IPC分类号： C07D471/04 ,  C07D519/00

CPC分类号： C07D471/04 ,  C07D519/00

摘要： The present invention relates to a novel compound having a histone deacetylase 6 (HDAC6) inhibitory activity, an isomer thereof or a pharmaceutically acceptable salt thereof, the use thereof for preparing a therapeutic medicament; a pharmaceutical composition containing the same, and a treatment method using the composition; and a preparation method thereof. The novel compound, the isomer thereof, or the pharmaceutically acceptable salt thereof according to the present invention has the HDAC6 inhibitory activity, which is effective in the prevention or treatment of HDAC6-mediated diseases including cancer, inflammatory diseases, autoimmune diseases, neurological or neurodegenerative diseases.

公开(公告)号：US10717716B2

公开(公告)日：2020-07-21

申请号：US15750067

申请日：2016-08-04

申请人： Chong Kun Dang Pharmaceutical Corp.

发明人： Jaekwang Lee ,  Yuntae Kim ,  Chang Sik Lee ,  Hyeseung Song ,  Dal-Yong Gwak ,  Jaeyoung Lee ,  Jung Taek Oh ,  Chang Gon Lee ,  Il Hyang Kim

IPC分类号： C07D271/10 ,  C07D413/12 ,  C07D491/10 ,  C07D413/04 ,  A61P25/00 ,  C07D471/10 ,  A61P37/00 ,  C07D413/14 ,  C07D417/12 ,  A61P29/00 ,  C07D417/14 ,  A61P35/00

摘要： The present invention relates to novel compounds having histone deacetylase 6 (HDAC6) in-hibitory activity, stereoisomers thereof or pharmaceutically acceptable salts thereof the use thereof for the preparation of therapeutic medicaments, pharmaceutical compositions containing the same, a method for treating diseases using the composition, and methods for preparing the novel compounds. The novel compounds stereoisomers thereof or pharmaceutically acceptable salts thereof according to the present invention have histone deacetylase (HDAC) inhibitory activity and are effective for the prevention or treatment of HDAC6-mediated diseases, including infectious diseases; neoplasms; endocrine, nutritional and metabolic diseases; mental and be-havioral disorders; neurological diseases; diseases of the eye and adnexa; cardiovascular diseases; respiratory diseases; digestive diseases; diseases of the skin and subcutaneous tissue; diseases of the musculoskeletal system and connective tissue; or congenital malformations, deformations and chromosomal abnormalities.